A new risk assessment tool for GPs is set to revolutionise PCa diagnosis. See here. And NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers. See here.

Patients might be offered a more accurate prediction of their PCa risk with a novel method developed by Cambridge University researchers. See here

Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits are officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who don’t have a clinically significant PCa. See here. Latest on this here.